- Trials with a EudraCT protocol (32)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
32 result(s) found for: Dyspareunia AND Pain.
Displaying page 1 of 2.
EudraCT Number: 2017-004066-10 | Sponsor Protocol Number: MVT-601-3103 | Start Date*: 2018-10-19 | |||||||||||
Sponsor Name:Myovant Sciences GmbH | |||||||||||||
Full Title: SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered with Low-Dose Estradiol and Norethindrone Acetate in Wom... | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) BE (Completed) FI (Completed) SE (Completed) PL (Completed) CZ (Completed) BG (Completed) PT (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004833-10 | Sponsor Protocol Number: EC12/2017 | Start Date*: 2018-01-15 |
Sponsor Name:Fundación para la Investigación Biomédica | ||
Full Title: Clinical trial ramdomized for treatment of perineal pain and dyspareunia portpartum through local anesthetic infiltrations vs anesthetic and corticoids | ||
Medical condition: perineal pain and dyspareunia postpartum | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-006147-25 | Sponsor Protocol Number: UTEROXINE | Start Date*: 2022-11-15 | |||||||||||||||||||||||||||||||
Sponsor Name:Centre de Recherche en Santé de la Femme | |||||||||||||||||||||||||||||||||
Full Title: Botulinum toxin type A injection in patients with chronic pelvic pain of uterine origin (severe dysmenorrhea and/or deep dyspareunia). Phase III, single-center, randomized study vs. control group | |||||||||||||||||||||||||||||||||
Medical condition: PATIENTS WITH CHRONIC PELVIC PERINEAL PAIN OF UTERINE ORIGIN WITH VAS>4 | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002199-28 | Sponsor Protocol Number: VFCr-12/2015 | Start Date*: 2016-10-11 | |||||||||||
Sponsor Name:Dr. August Wolff GmbH & Co. KG Arzneimittel | |||||||||||||
Full Title: Prospective, open-label, multicenter, multinational, randomized trial to investigate the non-inferiority of treatment with Vagisan® Moisturising Cream in comparison to an Estriol containing cream i... | |||||||||||||
Medical condition: postmenopausal women suffering from symptoms of vulvovaginal dryness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004043-21 | Sponsor Protocol Number: 16-OBE2109-016 | Start Date*: 2018-10-17 |
Sponsor Name:ObsEva SA | ||
Full Title: An exploratory, single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily For 12 weeks followed by 100 mg daily for 12 weeks in rectovaginal endometriosis. | ||
Medical condition: Rectovaginal endometriosis | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-001588-19 | Sponsor Protocol Number: MVT-601-3101 | Start Date*: 2017-11-01 | |||||||||||
Sponsor Name:Myovant Sciences GmbH | |||||||||||||
Full Title: SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Ac... | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) HU (Completed) BE (Completed) PL (Completed) BG (Completed) PT (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002325-30 | Sponsor Protocol Number: VMP-03/2018 | Start Date*: 2019-09-18 | |||||||||||
Sponsor Name:Dr. August Wolff GmbH & Co. KG Arzneimittel | |||||||||||||
Full Title: Prospective, open-label, monocenter, trial to investigate the efficacy and tolerability of Vagisan® a lactic acid containing vaginal suppository, in a panel of post-menopausal women suffering from... | |||||||||||||
Medical condition: vulvovaginal atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004042-14 | Sponsor Protocol Number: 16-OBE2109-015 | Start Date*: 2018-04-23 | |||||||||||
Sponsor Name:ObsEva SA | |||||||||||||
Full Title: An exploratory single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks in uterine adenomyosis. | |||||||||||||
Medical condition: Uterine adenomyosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002791-14 | Sponsor Protocol Number: 1707-CL-0011 | Start Date*: 2013-02-14 | |||||||||||
Sponsor Name:Astellas Pharma Europe B.V. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects with Endometriosis Associated Pelvic Pain for 12 ... | |||||||||||||
Medical condition: endometriosis associated pelvic pain | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) GB (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001632-19 | Sponsor Protocol Number: MVT-601-3102 | Start Date*: 2017-12-01 | |||||||||||
Sponsor Name:Myovant Sciences GmbH | |||||||||||||
Full Title: SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Ac... | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) PL (Completed) GB (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000068-10 | Sponsor Protocol Number: 3142A2-203 | Start Date*: 2006-09-04 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | ||
Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 75 MG AND 150 MG DOSES OF ERB-041 ON THE REDUCTION OF SYMPTOMS ASSOCIATED WITH ENDOMETRIOSIS DURING TREAT... | ||
Medical condition: Reproductive-aged women with moderate to severe symptoms related to endometriosis. Subjects will have been diagnosed with endometriosis by laparoscopy or laparotomy within 10 years before visit 1B ... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-001736-35 | Sponsor Protocol Number: 15-OBE2109-001 | Start Date*: 2016-08-29 | |||||||||||||||||||||
Sponsor Name:ObsEva SA | |||||||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, phase 2b dose-ranging study to assess the efficacy and safety of OBE2109 in subjects with endometriosis associated pain. | |||||||||||||||||||||||
Medical condition: Treatment of Endometriosis-Associated Pain | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001296-23 | Sponsor Protocol Number: 61409 | Start Date*: 2019-06-03 |
Sponsor Name:Radboudumc | ||
Full Title: The efficacy of botulinum toxin A injection in pelvic floor muscles in chronic pelvic pain patients: a double-blinded randomised controlled trial | ||
Medical condition: Patients with >6 months or recurrent episodes of abdomino-perineo-pelvic pain, hypersensitivity or discomfort often associated with elimination changes, and sexual dysfunction in the absence of org... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004752-21 | Sponsor Protocol Number: ISI-06-01 | Start Date*: 2006-11-08 | |||||||||||
Sponsor Name:Karolinska Institute, Danderyds hospital | |||||||||||||
Full Title: Pertubation with Lignocaine in Endometriosis Associated Symptoms Effect study (PLEASE) | |||||||||||||
Medical condition: Women 20-40 years of age with endometriosis and pelvic pain will be included in this study. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001047-31 | Sponsor Protocol Number: M12-821 | Start Date*: 2014-05-14 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain | |||||||||||||
Medical condition: Moderate to Severe Endometriosis Associated Pain | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) AT (Completed) IT (Completed) ES (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000375-25 | Sponsor Protocol Number: BotA-KKDS2016 | Start Date*: 2016-04-19 |
Sponsor Name:Danderyds sjukhus AB | ||
Full Title: Double blind placebo-controlled RCT of the efficacy and safety of intramuscular injections of Botulinum Toxin A as a treatment for provoked vestibulodynia | ||
Medical condition: Provoked vestibulodynia | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002367-26 | Sponsor Protocol Number: CLI18001/Lita-003 | Start Date*: 2019-03-27 | |||||||||||
Sponsor Name:Litaphar Laboratorios | |||||||||||||
Full Title: A randomized, double-blind, three-arm, parallel-group, multicentre superiority study assessing the efficacy and safety of mifepristone (2.5 mg and 5 mg) vs. placebo for the treatment of endometrios... | |||||||||||||
Medical condition: endometriosis in reproductive-age | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001720-21 | Sponsor Protocol Number: TAK-013/EC301 | Start Date*: 2004-12-24 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide ... | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001721-13 | Sponsor Protocol Number: TAK-013/EC-302 | Start Date*: 2005-01-24 | |||||||||||
Sponsor Name:Takeda Europe R&D Center Ltd | |||||||||||||
Full Title: A Phase III, multi-center, randomized, double-blind study to evaluate the efficacy and safety of 50 mg and 100 mg of sufugolix (TAK-013) tablets administered twice daily versus placebo for 12 weeks... | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005035-13 | Sponsor Protocol Number: GaPP2 | Start Date*: 2015-02-13 | |||||||||||
Sponsor Name:University of Edinburgh [...] | |||||||||||||
Full Title: GaPP 2: A multi-centre randomised controlled trial of the efficacy and mechanism of action of gabapentin for the management of chronic pelvic pain in women | |||||||||||||
Medical condition: Chronic pelvic pain of unknown cause | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
